# US 2003/0211498 A1 · Tumor markers in ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211498 A1
- Document ID: US20030211498A1
- Status: Published application
- Kind: A1
- Application number: 10/257,021
- Filed: 2002-10-03
- Published: 2003-11-13
- Earliest claimed: 2002-10-03
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, NIH
- Inventors: Patrice J Morin; Cheryl A Sherman-Baust; Ellen S Pizer; Colleen D Hough
- Web page: https://patentgrep.com/patent/US20030211498A1

## CPC

- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

## Claims

### Claim 1

A method of detecting an ovarian tumor in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not having an ovarian tumor, detects an ovarian tumor in said subject.

### Claim 2

A method of identifying a subject at increased risk for developing ovarian cancer, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not at increased risk for developing ovarian cancer, identifies an individual at increased risk for developing ovarian cancer.

### Claim 3

A method of determining the effectiveness of an ovarian cancer treatment in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject after treatment of said subject, wherein a modulation in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in said subject prior to said treatment, indicates an effective ovarian cancer treatment in said subject.

### Claim 4 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined in said subject by measuring the expression level of said tumor marker gene in a sample from said subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein said sample from said subject is selected from the group consisting of a tissue biopsy, ovarian epithelial cell scrapings, peritoneal fluid, blood, urine, and serum.

### Claim 6 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is measured in vivo in said subject.

### Claim 7 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is determined by measuring the level of ovarian tumor marker mRNA.

### Claim 8 (depends on 7)

The method of claim 7, wherein said level of ovarian tumor marker mRNA is measured using RT-PCR, Northern hybridization, dot-blotting, or in situ hybridization.

### Claim 9 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined by measuring the level of ovarian tumor marker polypeptide encoded by said ovarian tumor marker gene.

### Claim 10 (depends on 9)

The method of claim 9, wherein said level of ovarian tumor marker polypeptide is measured by ELISA, immunoblotting, or immunohistochemistry.

### Claim 11 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is compared to the expression level of said tumor marker gene in a reference subject diagnosed with ovarian cancer.

### Claim 12 (depends on 2)

The method of claim 2, wherein said expression level of said ovarian tumor marker gene in said subject is compared to the expression level of said tumor marker gene in a reference subject that is identified as having an increased risk for developing ovarian cancer.

### Claim 13

A method of identifying a tumor as an ovarian tumor, said method comprising measuring the expression level of an ovarian tumor marker gene in a tumor cell from said tumor, wherein an increase in said expression level of said ovarian tumor marker gene in said tumor cell, relative to the expression level of said ovarian tumor marker gene in a noncancerous ovarian cell, identifies the tumor as an ovarian tumor.

### Claim 14

A method of treating or preventing an ovarian tumor in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in an ovarian epithelial cell in said subject.

### Claim 15

A method of inhibiting the growth or metastasis of an ovarian tumor cell in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in said ovarian tumor cell in said subject.

### Claim 16

A method of inhibiting the growth or metastasis of an ovarian tumor in a subject, said method comprising contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide encoded by an ovarian tumor marker gene, wherein the binding of said antibody to said ovarian tumor marker polypeptide inhibits the growth or metastasis of said ovarian tumor in said subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein said ovarian tumor marker polypeptide is on the surface of said ovarian tumor cell.

### Claim 18 (depends on 16)

The method of claim 16, wherein said antibody is coupled to a radioisotope or a toxic compound.

### Claim 19

A method of diagnosing ovarian cancer in a subject, said method comprising measuring the amount of an ovarian tumor marker polypeptide in said subject, wherein an amount of ovarian tumor marker polypeptide that is greater than the amount of ovarian tumor marker polypeptide measured in a subject not having ovarian cancer diagnoses an ovarian cancer in the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein said ovarian tumor marker polypeptide is present at the surface of a cell.

### Claim 21 (depends on 19)

The method of claim 19, wherein said ovarian tumor marker polypeptide is in soluble form.

### Claim 22 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96)1; HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.

### Claim 23 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione perroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apoplipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

### Claim 24 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-Iib).

### Claim 25 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

### Claim 26 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

### Claim 27 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.

### Claim 28 (depends on 1, 2, 3, 13, 14, 15, 16)

The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor is an epithelial ovarian tumor.

### Claim 29 (depends on 28)

The method of claim 28, wherein said epithelial ovarian tumor is selected from the group consisting of a serous cystadenoma, a borderline serous tumor, a serous cystadenocarcinoma, a mucinous cystadenoma, a borderline mucinous tumor, a mucinous cystadenocarcinoma, an endometrioid carcinoma, an undifferentiated carcinoma, a clear cell adenocarcinoma, a cystadenofibroma, an adenofibroma, and a Brenner tumor.

### Claim 30

A kit comprising an antibody for measuring the expression level of an ovarian tumor marker gene in a subject.

### Claim 31

A kit comprising a nucleic acid for measuring the expression level of an ovarian tumor marker gene in a subject.

### Claim 32 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96)1; HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.

### Claim 33 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione perroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apoplipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (13CAM); collagen type III, alpha-1; Mal CT cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

### Claim 34 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-Iib).

### Claim 35 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

### Claim 36 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

### Claim 37 (depends on 30, 31)

The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.
